Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA

Overview

Journal Am J Clin Pathol

Publisher Oxford University Press

Specialty Pathology

Date 2022 Mar 14

PMID 35285877

Authors

Kyung-Hwa Shin

Sun Min Lee

Kongkyoung Park

Hyunji Choi

In-Suk Kim

Seong Hoon Yoon

Seung Hwan Oh

Affiliations

Soon will be listed here.

Abstract

Objectives: Various preanalytical factors, including the collection tube, storage conditions, and centrifugation, affect the detection results of plasma cell-free DNA (cfDNA). We compared the effect of different centrifugation protocols on the detection of EGFR mutations in cfDNA.

Methods: We analyzed 117 plasma specimens from 110 patients with non-small cell lung cancer using the cobas EGFR Mutation Test v2 (Roche Diagnostics). We compared the identified EGFR mutations and semiquantitative index values from the 1- and 2-step centrifugation groups and confirmed the clinical impact of differences in the results after further high-speed centrifugation.

Results: We detected EGFR mutations in 44 (37.6%) and 47 (40.2%) samples that were centrifuged once and twice, respectively; the 2 groups showed an 89.7% (105/117) concordance and a strong correlation in their semiquantitative index values (r = 0.929). Among the 12 inconsistent result pairs, 9 samples of 2-step centrifugation (75%) were consistent with the results of a recent tissue biopsy.

Conclusions: Additional high-speed centrifugation has been shown to increase the sensitivity of EGFR mutation detection in a commercial in vitro diagnostic real-time polymerase chain reaction device and is an optimal preanalytical factor for detecting low-allele frequency gene mutations using low concentrations of cfDNA.

Citing Articles

Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients.

Kang Y, Shin D, Park J, Hwang C, Lee H, Lee J J Pathol Transl Med. 2025; 59(1):60-67.

PMID: 39815744 PMC: 11736281. DOI: 10.4132/jptm.2024.10.01.

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples.

Peng H, Pan M, Zhou Z, Chen C, Xing X, Cheng S Front Cell Dev Biol. 2024; 12:1385041.

PMID: 38784382 PMC: 11111958. DOI: 10.3389/fcell.2024.1385041.

Pre-Analytical Factors Affecting Extracellular DNA in Saliva.

Janovicova L, Holaniova D, Vlkova B, Celec P Diagnostics (Basel). 2024; 14(3).

PMID: 38337765 PMC: 10855236. DOI: 10.3390/diagnostics14030249.

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study.

Fujii H, Nagakura H, Kobayashi N, Kubo S, Tanaka K, Watanabe K BMC Cancer. 2022; 22(1):1035.

PMID: 36192767 PMC: 9531433. DOI: 10.1186/s12885-022-10135-z.

References

Grolz D, Hauch S, Schlumpberger M, Guenther K, Voss T, Sprenger-Haussels M . Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows-Venous Whole Blood and Plasma. Curr Pathobiol Rep. 2019; 6(4):275-286. PMC: 6290703. DOI: 10.1007/s40139-018-0180-z. View

Sorber L, Zwaenepoel K, Jacobs J, De Winne K, Goethals S, Reclusa P . Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Cancers (Basel). 2019; 11(4). PMC: 6521186. DOI: 10.3390/cancers11040458. View

Arcila M, Oxnard G, Nafa K, Riely G, Solomon S, Zakowski M . Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011; 17(5):1169-80. PMC: 3070951. DOI: 10.1158/1078-0432.CCR-10-2277. View

ODonnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J . Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013; 13:210. PMC: 3660201. DOI: 10.1186/1471-2407-13-210. View

Marchetti A, Palma J, Felicioni L, De Pas T, Chiari R, Del Grammastro M . Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol. 2015; 10(10):1437-43. DOI: 10.1097/JTO.0000000000000643. View

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View

Kuiper J, Heideman D, Thunnissen E, Paul M, van Wijk A, Postmus P . Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer. 2014; 85(1):19-24. DOI: 10.1016/j.lungcan.2014.03.016. View

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v1-v27. DOI: 10.1093/annonc/mdw326. View

Olsen D, Jorgensen J . Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol. 2014; 4:105. PMC: 4032883. DOI: 10.3389/fonc.2014.00105. View

10.

Kohsaka S, Petronczki M, Solca F, Maemondo M . Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2018; 15(6):637-652. DOI: 10.2217/fon-2018-0736. View

11.

Esteva-Socias M, Enver-Sumaya M, Gomez-Bellvert C, Guillot M, Azkarate A, Marse R . Detection of the G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR. Front Med (Lausanne). 2020; 7:594900. PMC: 7691481. DOI: 10.3389/fmed.2020.594900. View

12.

Macias M, Alegre E, Alkorta-Aranburu G, Patino-Garcia A, Mateos B, Andueza M . The Dynamic Use of Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Dis Markers. 2019; 2019:7954921. PMC: 6364099. DOI: 10.1155/2019/7954921. View

13.

Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K . EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci. 2006; 97(8):753-9. PMC: 11158750. DOI: 10.1111/j.1349-7006.2006.00233.x. View

14.

Kim E, Cho E, Park H, Hong J, Lim S, Youn J . Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016; 17(3):237-45. PMC: 4848002. DOI: 10.1080/15384047.2016.1139235. View

15.

Kim Y, Shin S, Lee K . A Comparative Study for Detection of Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories. Biomed Res Int. 2018; 2018:7392419. PMC: 5964486. DOI: 10.1155/2018/7392419. View

16.

Burrell R, Swanton C . Re-Evaluating Clonal Dominance in Cancer Evolution. Trends Cancer. 2017; 2(5):263-276. DOI: 10.1016/j.trecan.2016.04.002. View

17.

Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y . First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience. Cancer Commun (Lond). 2018; 38(1):51. PMC: 6064043. DOI: 10.1186/s40880-018-0321-0. View

18.

Zhang G, Lin J, Wang Z, Zhou Q, Xu C, Zhu J . Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol). 2007; 19(7):499-506. DOI: 10.1016/j.clon.2007.04.006. View

19.

Xu T, Kang X, You X, Dai L, Tian D, Yan W . Cross-Platform Comparison of Four Leading Technologies for Detecting Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma. Theranostics. 2017; 7(6):1437-1446. PMC: 5436504. DOI: 10.7150/thno.16558. View

20.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View